Get the latest news, insights, and market updates on BCRX (BioCryst Pharmaceuticals, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as of November 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Lis Nov 5, 2025 - $BCRX
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 12:00 p.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company f Nov 5, 2025 - $BCRX
BioCryst Pharmaceuticals (BCRX) Is Up After Raising ORLADEYO Outlook and Returning to Profitability – What’s Changed
BioCryst Pharmaceuticals recently reported third quarter 2025 results with revenue rising to US$159.4 million and net income reaching US$12.9 million, while also increasing its full-year revenue guidance for global ORLADEYO sales to between US$590 million and US$600 million. The company returned to profitability and announced the appointment of a new Chief Commercial Officer, suggesting continued business momentum and leadership stability. We'll examine how BioCryst's raised ORLADEYO revenue... Nov 4, 2025 - $BCRX
BioCryst Pharmaceuticals (BCRX): Forecasts Call for 56.3% Annual Earnings Growth Heading Into Earnings Season
BioCryst Pharmaceuticals (BCRX) remains unprofitable but has narrowed its losses at a 15.9% annual pace over the last five years. Earnings are now forecast to surge 56.3% per year and reach profitability within three years. Revenue growth is projected at 13.8% per year, outpacing the US market’s 10.5% benchmark. Shares currently trade at $6.86, well below a discounted cash flow fair value estimate of $75.71. Despite challenges such as negative equity and the absence of sustained profit... Nov 4, 2025 - $BCRX
BioCryst (BCRX) Q3 2025 Earnings Call Transcript
John Stonehouse: Thank you, Nick. Starting with Orladeyo, we continue to see strong revenue growth year over year on a growing revenue base, well on our way to $1 billion at peak. This not only cleaned up our balance sheet but put us in a very strong financial position, generating operating profit and positive cash flow. Nov 3, 2025 - $BCRX
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued improvement in non-GAAP operating profit margin from strong operating leverage— —ORLADEYO FY 2025 revenue guidance raised to between $590 to $600 million; FY 2025 non-GAAP operating expense guidance lowered to between $430 to $440 million— —Sale of European ORLADEYO business completed; proc Nov 3, 2025 - $BCRX
BioCryst: Q3 Earnings Snapshot
DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. BCRX) on Monday reported third-quarter net income of $12.9 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Durham, North Carolina-based company said it had profit of 6 cents. Nov 3, 2025 - $BCRX
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +10.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Oct 30, 2025 - $BCRX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple